ClinicalTrials.gg
CompletedNCT01253304Updated Oct 7, 2014Results posted

A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment

A Phase 1 interventional study of LY2189265 in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
50th of 54
26 · median 159
Started
2010
with 6 others
Phase 1
15 of 54
none open now
Registered
11th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 50th largest by enrollment, is one of 7 that started in 2010, is one of 15 in phase 1, and was the 11th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The primary purpose of this study is to help answer the following research questions, and not to provide treatment for any condition:

  • To evaluate how much of the study drug (LY2189265) is in the blood of participants with varying degrees of liver impairment compared to those with normal liver function.
  • To assess the safety of LY2189265 and any side effects that might be associated with it.
03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants (including participants with type 2 diabetes mellitus [T2DM]):

  • Male participants - Agree to use a reliable method of (for example, barrier methods) during the study and for at least 3 months following dosing of study drug
  • Female participants:

    • Women must be of non- due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation) or menopause
    • Women with an intact uterus are deemed if they are over 45 years old and have had cessation of menses for at least 1 year or have had 6 to 12 months of spontaneous amenorrhea with follicle stimulating hormone (FSH) >40 international units per milliliter (IU/mL) and have not taken hormone replacement therapy or oral contraceptives within 1 year of study start and are otherwise healthy
    • Women who have had cessation of menses for at least 2 years are permitted to take hormone replacement therapy
  • Have a (BMI) between 19.0 and 40.0 kilograms per meters squared (kg/m\^2), inclusive, at screening.
  • Have venous access sufficient to allow blood sampling
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
  • Have given written approved by Lilly and the ethical review board governing the site

Control Participants:

  • Overtly healthy participants with normal hepatic function
  • Participants with T2DM with normal hepatic function
  • Have normal sitting blood pressure and pulse rate as determined by the investigator or with changes compatible with their age and disease status in case of patients with T2DM
  • Have clinical laboratory test results within normal reference range for the investigator site or results with minor deviations not considered to be by the investigator or with changes compatible with their age and disease status in case of T2DM

Hepatic Impaired Participants:

  • Have stable hepatic impairment (such as, post-alcoholic, chronic hepatitis, biliary cirrhosis, or cryptogenic) classified as Class A, B, or C (mild, moderate, and severe impairment) who are considered by the investigator as acceptable for participation in the study. The hepatic-impaired participant population may include patients with T2DM.
  • Have sitting blood pressure and pulse rate compatible with their disease state [including T2DM, if applicable] as determined by the investigator.

Participants with T2DM (All Study Groups)

  • Have T2DM controlled with diet and exercise alone or T2DM is stable on a single, oral agent antihyperglycemic medication (metformin, sulfonylureas, repaglinide, nateglinide, acarbose [or other disaccharidase inhibitors], or thiazolidinediones) for at least 3 weeks (3 months for thiazolidinediones) prior to admission
  • Have a glycosylated () value at screening (or within 4 weeks prior to screening) of 6.5% to 9.0%
  • Have clinical laboratory test results within normal range or deemed clinically insignificant by the investigator. Abnormalities of serum glucose, serum lipids, urinary glucose, and urinary protein consistent with T2DM are acceptable
  • Have acceptable blood pressure and pulse rate (sitting), as determined by the investigator

Exclusion criteria

Exclusion Criteria:

All participants (including participants with T2DM)

  • Are currently enrolled in, discontinued within the last 30 days from a clinical trial involving use of an drug or device other than the study drug, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have known allergies to LY2189265 or related compounds
  • Have previously completed or withdrawn from this study or any other study investigating LY2189265
  • Have a current, functioning organ transplant
  • Show evidence of significant active, uncontrolled, endocrine or abnormalities (such as, thyroid disease or pernicious anemia) as judged by the screening physician
  • Have shown febrile illness within 3 days prior to screening
  • Have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening that are not otherwise explained by permitted concomitant medications
  • Show evidence of (HIV) and/or positive human HIV antibodies
  • Are women with a positive pregnancy test or women who are lactating
  • Have donated blood of more than 500 milliliters (mL) within the last month prior to screening
  • Have an average weekly alcohol intake that exceeds 21 units per week (men) and 14 units per week (women) (1 unit = 12 ounces [oz] or 360 mL of beer, 5 oz or 150 mL of wine, or 1.5 oz or 45 mL of distilled spirits)
  • Are unwilling to stop alcohol consumption for the duration of the study (from screening until the follow-up visit)
  • Are participants who smoke more than 10 cigarettes per day, are unwilling to refrain from smoking on the day of LY2189265 administration, or are unable to abide by clinical research unit (CRU) restrictions on other inpatient days
  • Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder, (for example relevant esophageal reflux or gall bladder disease, or any gastrointestinal disease which impacts gastric emptying [such as, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy] or could be aggravated by glucagon like peptide [GLP] analogs). Participants with mild hypertension and dyslipidemia, and participants who had cholecystolithiasis (removal of gall stones) and/or cholecystectomy (removal of gall bladder) in the past, with no further sequelae, may be included in the study at the discretion of the screening physician.
  • Are participants deemed to be unsuitable by the investigator for any reason.

Control participants:

  • Have a history or presence of cardiovascular (such as, myocardial infarction, cerebrovascular accident, venous thromboembolism), respiratory, renal, endocrine (with exception of participants with T2DM), hematological, neurological disorders, cancer, hepatic (including Gilbert's disease), or dermatological disorders or diseases capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Show evidence of significant active neuropsychiatric disease
  • Have less than 80 milliliters per minute (mL/min) (as calculated by the Cockcroft-Gault equation)
  • Show evidence of and/or positive hepatitis B surface antigen
  • Show evidence of and/or positive hepatitis C antibody
  • Intend to use:

    • Over-the-counter medication (including herbal remedies/health supplements) within 7 days prior to dosing
    • Prescription medication within 14 days prior to dosing participants with mild, moderate, and severe hepatic impairment
  • Show evidence of any significant active disease other than that responsible for or associated with hepatic impairment. Participants with hypertension and hyperlipidemia may be permitted at the investigator's discretion.
  • Show, in the opinion of the investigator, evidence of significant neuropsychiatric disease other than Grade 1 hepatic encephalopathy
  • Show evidence of spontaneous bacterial peritonitis within 6 months of dosing.
  • Show evidence of severe hyponatremia (Sodium [Na] \<120 millimoles per liter [mmol/L])
  • Show presence of hepatocellular carcinoma
  • Have a portal shunt
  • Show evidence of severe ascites
  • Have \<9.0 grams per deciliter (g/dL)
  • Have count \<40 x 10\^9 cells per liter (cells/L)
  • Have total serum >15 milligrams per deciliter (mg/dL)
  • Use medication known to interfere with hepatic metabolism (that is, barbiturates, phenothiazines) or known to alter other major organs or systems

Mild, Hepatic Impaired Participants ( A)

  • Show evidence of active renal disease with creatinine clearance \<70 mL/min calculated by the Cockcroft-Gault equation.
  • Moderate and Severe Hepatic Impaired Subjects (Child-Pugh B and C)
  • Show evidence of hepatorenal syndrome as shown by creatinine clearance \<50 mL/min calculated by the Cockcroft-Gault equation.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Normal hepatic function

    LY2189265: A single, subcutaneous (SC) 1.5-milligram (mg) injection on Day 1 in participants with normal hepatic function

    Drug: LY2189265

  • Experimental
    Mild hepatic impairment

    LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with mild hepatic impairment (Child-Pugh A)

    Drug: LY2189265

  • Experimental
    Moderate hepatic impairment

    LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with moderate hepatic impairment (Child-Pugh B)

    Drug: LY2189265

  • Experimental
    Severe hepatic impairment

    LY2189265: A single, SC-1.5 mg injection on Day 1 in participants with severe hepatic impairment (Child-Pugh C)

    Drug: LY2189265

Interventions

  • Subcutaneous (SC) injection

    Also known as: Dulaglutide

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Maximum Observed Concentration (Cmax)

    This measure was calculated using non-compartmental analysis techniques.

    Time frame: Predose to 336 hours postdose

  2. Pharmacokinetics: Time of Maximum Concentration (Tmax)

    This measure was calculated using non-compartmental analysis techniques.

    Time frame: Predose to 336 hours postdose

  3. Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC[0-tlast])

    This measure was calculated using non-compartmental analysis techniques.

    Time frame: Predose to 336 hours postdose

  4. Pharmacokinetics: AUC From Time Zero to Infinity (AUC[0-infinity])

    This measure was calculated using non-compartmental analysis techniques.

    Time frame: Predose to 336 hours postdose

  5. Pharmacokinetics: Apparent Terminal Elimination Half-life (t1/2)

    The half life associated with the terminal rate constant is summarized. This measure was calculated using non-compartmental analysis techniques.

    Time frame: Predose to 336 hours postdose

  6. Pharmacokinetics: Apparent Total Plasma Clearance (CL/F)

    The apparent total body clearance of drug calculated after extra vascular administration is summarized. This measure was calculated using non-compartmental analysis techniques.

    Time frame: Predose to 336 hours postdose

  7. Pharmacokinetics: Apparent Volume of Distribution (Vz/F)

    The apparent volume of distribution during the terminal phase after extra vascular administration is summarized. This measure was calculated using non-compartmental analysis techniques.

    Time frame: Predose to 336 hours postdose

07

Results

Posted Oct 7, 2014

Participant flow

Participant flow — Overall Study
MilestoneNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Started11663
Received at least 1 dose of study drug11663
Completed11662
Not completed0001
Withdrew: Adverse event0001

Outcome measures

PrimaryPharmacokinetics: Maximum Observed Concentration (Cmax)

This measure was calculated using non-compartmental analysis techniques.

Time frame:
Predose to 336 hours postdose
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Pharmacokinetics: Maximum Observed Concentration (Cmax)
nanograms/milliliter (ng/mL)Normal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Pharmacokinetics: Maximum Observed Concentration (Cmax)84.5 ± 2963.0 ± 3058.1 ± 2861.3 ± 18
PrimaryPharmacokinetics: Time of Maximum Concentration (Tmax)

This measure was calculated using non-compartmental analysis techniques.

Time frame:
Predose to 336 hours postdose
Reported as:
Median · hours
Pharmacokinetics: Time of Maximum Concentration (Tmax)
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Pharmacokinetics: Time of Maximum Concentration (Tmax)48.00 (24.02 to 72.02)48.01 (47.95 to 72.02)59.96 (47.10 to 95.97)71.93 (71.90 to 71.98)
PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC[0-tlast])

This measure was calculated using non-compartmental analysis techniques.

Time frame:
Predose to 336 hours postdose
Reported as:
Geometric mean · nanograms times hour/milliliter(ng*hr/mL
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC[0-tlast])
nanograms times hour/milliliter(ng*hr/mLNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC[0-tlast])10200 ± 267670 ± 277220 ± 197660 ± 13
PrimaryPharmacokinetics: AUC From Time Zero to Infinity (AUC[0-infinity])

This measure was calculated using non-compartmental analysis techniques.

Time frame:
Predose to 336 hours postdose
Reported as:
Geometric mean · nanograms times hr/milliliter (ng*hr/mL)
Pharmacokinetics: AUC From Time Zero to Infinity (AUC[0-infinity])
nanograms times hr/milliliter (ng*hr/mL)Normal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Pharmacokinetics: AUC From Time Zero to Infinity (AUC[0-infinity])16300 ± 2412200 ± 2611200 ± 1412500 ± 5
PrimaryPharmacokinetics: Apparent Terminal Elimination Half-life (t1/2)

The half life associated with the terminal rate constant is summarized. This measure was calculated using non-compartmental analysis techniques.

Time frame:
Predose to 336 hours postdose
Reported as:
Geometric mean · hours
Pharmacokinetics: Apparent Terminal Elimination Half-life (t1/2)
hoursNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Pharmacokinetics: Apparent Terminal Elimination Half-life (t1/2)104 (88.6 to 116)101 (86.2 to 116)88.2 (75.1 to 104)99.2 (76.4 to 121)
PrimaryPharmacokinetics: Apparent Total Plasma Clearance (CL/F)

The apparent total body clearance of drug calculated after extra vascular administration is summarized. This measure was calculated using non-compartmental analysis techniques.

Time frame:
Predose to 336 hours postdose
Reported as:
Geometric mean · liters/hour (L/h)
Pharmacokinetics: Apparent Total Plasma Clearance (CL/F)
liters/hour (L/h)Normal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Pharmacokinetics: Apparent Total Plasma Clearance (CL/F)0.0920 ± 240.123 ± 260.135 ± 140.120 ± 5
PrimaryPharmacokinetics: Apparent Volume of Distribution (Vz/F)

The apparent volume of distribution during the terminal phase after extra vascular administration is summarized. This measure was calculated using non-compartmental analysis techniques.

Time frame:
Predose to 336 hours postdose
Reported as:
Geometric mean · liters (L)
Pharmacokinetics: Apparent Volume of Distribution (Vz/F)
liters (L)Normal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Pharmacokinetics: Apparent Volume of Distribution (Vz/F)13.8 ± 2717.9 ± 2717.1 ± 2017.1 ± 24

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Normal Hepatic Function—0/11 (0%)10/11 (90.9%)
Mild Hepatic Impairment—0/6 (0%)5/6 (83.3%)
Moderate Hepatic Impairment—1/6 (16.7%)5/6 (83.3%)
Severe Hepatic Impairment—1/3 (33.3%)1/3 (33.3%)
Most frequent serious events
Most frequent serious events
EventNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Acute hepatic failureHepatobiliary disorders0/110/60/61/3
Peritonitis bacterialInfections and infestations0/110/60/61/3
Status epilepticusNervous system disorders0/110/60/61/3
Renal failure acuteRenal and urinary disorders0/110/60/61/3
Iron deficiency anaemiaBlood and lymphatic system disorders0/110/61/60/3
Most frequent other events
Showing 10 of 33
Most frequent other events
EventNormal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic Impairment
Decreased appetiteMetabolism and nutrition disorders8/114/60/61/3
Disseminated intravascular coagulationBlood and lymphatic system disorders0/110/60/61/3
Heparin-induced thrombocytopeniaBlood and lymphatic system disorders0/110/60/61/3
EructationGastrointestinal disorders3/110/61/61/3
Gastrointestinal haemorrhageGastrointestinal disorders0/110/60/61/3
NauseaGastrointestinal disorders3/112/60/60/3
FatigueGeneral disorders1/110/61/61/3
Portal vein thrombosisHepatobiliary disorders0/110/60/61/3
Clostridial infectionInfections and infestations0/110/60/61/3
Lipase increasedInvestigations0/110/60/61/3

Baseline characteristics

Participants who received at least one dose of study drug (LY2189265).

Age, Continuous
Age, Continuous(years)Normal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Mean58.2 ± 8.556.3 ± 9.254.3 ± 4.864.3 ± 6.557.6 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Normal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Female644115
Male522211
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Normal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White1066325
More than one race10001
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Normal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Not Hispanic or Latino1166326
Hispanic or Latino00000
Region of Enrollment
Region of Enrollment(participants)Normal Hepatic FunctionMild Hepatic ImpairmentModerate Hepatic ImpairmentSevere Hepatic ImpairmentTotal
Germany1166326
08

Study locations

2 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Munich, 81241, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Budapest, 1032, Hungary
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2010
First posted
Dec 3, 2010
Start
Nov 2010
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Oct 7, 2014
Last update
Oct 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01253304
Responsible party
Sponsor
First posted
Dec 3, 2010
Start date
Nov 2010
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Oct 7, 2014
Last update
Oct 7, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion